GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 90 filers reported holding GRITSTONE ONCOLOGY INC in Q3 2023. The put-call ratio across all filers is 0.65 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,467 | -11.8% | 7,248 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $14,134 | +1.0% | 7,248 | +119.5% | 0.00% | 0.0% |
| Q1 2022 | $14,000 | -66.7% | 3,302 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $42,000 | +55.6% | 3,302 | +29.7% | 0.00% | 0.0% |
| Q3 2021 | $27,000 | +17.4% | 2,546 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $23,000 | -4.2% | 2,546 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $24,000 | +166.7% | 2,546 | +17.0% | 0.00% | – |
| Q4 2020 | $9,000 | +50.0% | 2,176 | 0.0% | 0.00% | – |
| Q3 2020 | $6,000 | -57.1% | 2,176 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $14,000 | +7.7% | 2,176 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $13,000 | -35.0% | 2,176 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $20,000 | +5.3% | 2,176 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $19,000 | -20.8% | 2,176 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $24,000 | +200.0% | 2,176 | +281.8% | 0.00% | – |
| Q1 2019 | $8,000 | -11.1% | 570 | 0.0% | 0.00% | – |
| Q4 2018 | $9,000 | – | 570 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
| Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
| Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
| Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
| Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
| Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
| SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
| Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
| CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
| Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |